'Quantamental' Japan Specialist, LightStream Research

Campbell Gunn

'Quantamental' Japan Specialist

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Thematic (Sector/Industry)

<p style="text-align: center;"><strong>• LARGE CAP RESULTS - 13th APRIL •</strong></p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/200/386/original/image_36527959121618346539491.png?1618346540" class="editor-image img-responsive" data-smartkarma-image-id="200386"></figure><div class="content-caption">Source for all charts &amp; tables: Japan Analytics</div><p><strong>RESULTS</strong> - Only 38% of Tuesdays 69 results announcements scored positively. Of the largest-cap stocks reporting, <a href="https://www.smartkarma.com/entities/toho-co-ltd" target="_blank" data-smartkarma-citation="entities:7806:1" rel="noopener">Toho (9602 JP)</a> cinemas has yet to bottom out but is still in profit. 'New wave' software companies <a href="https://www.smartkarma.com/entities/sansan-inc" target="_blank" data-smartkarma-citation="entities:28112:1" rel="noopener">Sansan (4443 JP)</a> and <a href="https://www.smartkarma.com/entities/money-forward-inc" target="_blank" data-smartkarma-citation="entities:25919:1" rel="noopener">Money Forward (3994 JP)</a> are growing into their extreme valuations, while <a href="https://www.smartkarma.com/entities/pasona-group-inc" target="_blank" data-smartkarma-citation="entities:15778:1" rel="noopener">Pasona's</a> under-appreciated margin transformation continues. </p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/200/403/original/image_63727914331618348873715.png?1618348877" class="editor-image img-responsive" data-smartkarma-image-id="200403"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/200/404/original/image_12260447541618348911606.png?1618348912" class="editor-image img-responsive" data-smartkarma-image-id="200404"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/200/405/original/image_35233699051618348944141.png?1618348944" class="editor-image img-responsive" data-smartkarma-image-id="200405"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/200/406/original/image_14670185761618348969100.png?1618348969" class="editor-image img-responsive" data-smartkarma-image-id="200406"></figure><p style="text-align: center;"><strong>• LARGE CAP FORECASTS/REVISIONS - 13th APRIL •</strong></p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/200/407/original/image_58511005871618349036093.png?1618349036" class="editor-image img-responsive" data-smartkarma-image-id="200407"></figure><p><strong>FORECASTS/REVISIONS</strong> - Two-thirds of annual forecasts/revisions were positive, with <a href="https://www.smartkarma.com/entities/toho-co-ltd" target="_blank" data-smartkarma-citation="entities:7806:1" rel="noopener">Toho (9602 JP)</a> and <a href="https://www.smartkarma.com/entities/j-front-retailing-co-ltd" target="_blank" data-smartkarma-citation="entities:8947:1" rel="noopener">J Front Retailing (3086 JP)</a> the leading largest-cap optimists. <a href="https://www.smartkarma.com/entities/santen-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:8602:1" rel="noopener">Santen Pharmaceutical (4536 JP)</a> revised down following a delay in the approval of glaucoma implant DE-128.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/200/408/original/image_63605452481618349380112.png?1618349381" class="editor-image img-responsive" data-smartkarma-image-id="200408"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/200/409/original/image_46822562891618349413296.png?1618349413" class="editor-image img-responsive" data-smartkarma-image-id="200409"></figure>

• LARGE CAP RESULTS - 13th APRIL •Source for all charts &amp; tables: Japan AnalyticsRESULTS - Only 38% of Tuesdays 69 results announcements scored positively. Of the largest-cap stocks reporting, Toho (9602 JP) cinemas has yet to bottom out but is still in profit. 'New wave' software companies Sansan (4443 JP) and Money Forward (3994 JP) are growing into their extreme valuations, while Pasona's under-appreciated margin transformation continues. • LARGE CAP FORECASTS/REVISIONS - 13th APRIL •FORECASTS/REVISIONS - Two-thirds of annual forecasts/revisions were positive, with Toho (9602 JP) and J Front Retailing (3086 JP) the leading largest-cap optimists. Santen Pharmaceutical (4536 JP) revised down following a delay in the approval of glaucoma implant DE-128.

🇯🇵 JAPAN • Results & Revisions 04/​​​​​​13 - Pasona (Grata) & J Front Retailing

Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

Why are investors buying into Oxford Biomedica (LN:OXB)? In this interview, BBC broadcaster Vivienne Parry OBE asks CEO John Dawson why Oxford Biomedica is so much more than a manufacturer of the AstraZeneca vaccine, which has propelled the company into the limelight. Watch now. 
 
See more content on Oxford Biomedica here: https://www.edisongroup.com/company/oxford-biomedica/776/
 
Oxford Biomedica (LN:OXB) is a global leader in cell and gene therapy. It has expanded its manufacturing facilities through Oxbox, an 84,000 sq ft state-of-the-art bioprocessing facility, significantly increasing its production capacity to match demand and to continue growing its revenues. In the near term, revenues will continue to be driven by the Novartis partnership for CAR-T Kymriah as the commercial roll-out continues and by the manufacturing agreement it has with AstraZeneca for its COVID-19 vaccine. OXB has established many cell and gene development and manufacturing partnerships, including with Novartis, Juno Therapeutics (BMS), Bioverativ (Sanofi), Orchard Therapeutics, Sio Gene Therapies, Boehringer Ingelheim, Santen, Beam Therapeutics and PhoreMost. OXB also has an 18-month supply agreement with AstraZeneca for the large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine, AZD1222.

Video: Oxford Biomedica – executive interview

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

Zhaoke Ophthalmology Pharmaceutical / Equity Capital Markets

<p>Zhaoke Ophthalmology is a pre-revenue pharmaceutical company specializing in ophthalmic drugs for the China market. The company has filed an Application Proof to list on the HKEX, and is a carve-out of <a href="https://www.smartkarma.com/entities/lee-s-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:14616:1" rel="noopener">Lee'S Pharmaceutical Hldgs (950 HK)</a> , which owns 34% of the shares. This Insight discusses the product pipelines (both innovative and generic), funding, and valuation (particularly in the context of the parent company).  We tag this Insight as Bullish for now.</p>

Zhaoke Ophthalmology is a pre-revenue pharmaceutical company specializing in ophthalmic drugs for the China market. The company has filed an Application Proof to list on the HKEX, and is a carve-out of Lee'S Pharmaceutical Hldgs (950 HK) , which owns 34% of the shares. This Insight discusses the product pipelines (both innovative and generic), funding, and valuation (particularly in the context of the parent company).  We tag this Insight as Bullish for now.

Zhaoke Ophthalmology: Bringing Focus to China

<section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/175/683/original/2020-12-01_09-00-54.png?1606780869" class="editor-image img-responsive" data-smartkarma-image-id="175683"></figure></section><div class="content-caption">Source for all charts &amp; tables: Japan Analytics </div><p><strong>FOUR QUADRANTS</strong> - By combining our two scoring methodologies - the Relative Price Score (RPS) and the Results &amp; Revision Score (RRS), we can assign companies into four quadrants:-</p><div>
<ul style="list-style-type: disc;">
<li>
<strong>CONTRARIAN BUYS</strong> - Low Results &amp; Revision and Relative Price Scores</li>
<li>
<strong>CONTRARIAN SELLS</strong> - High Results &amp; Revision and Relative Price Scores</li>
<li>
<strong>TURNAROUND BUYS </strong>- High Results &amp; Revision Scores &amp; low Relative Price Scores</li>
<li>
<strong>EX-GROWTH SELLS</strong> - Low Results &amp; Revision Scores &amp; high Relative Price Scores</li>
</ul>
<p>The Ex-Growth Sells quadrant offers more fertile ground for shorting as the decline in earnings momentum is already clear, however, in many cases, the market is reluctant to sell the 'darlings' of the past. Examples of profitable Ex-Growth Sells from 2020 are <a href="https://www.smartkarma.com/entities/kyudenko-corp" target="_blank" data-smartkarma-citation="entities:5414:1" rel="noopener">Kyudenko(1959 JP)</a>, <a href="https://www.smartkarma.com/entities/ariake-japan-co-ltd" target="_blank" data-smartkarma-citation="entities:4908:1" rel="noopener">Ariake Japan (2815 JP)</a>, and <a href="https://www.smartkarma.com/entities/santen-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:8602:1" rel="noopener">Santen Pharmaceutical (4536 JP)</a>. </p>
<section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/175/693/original/2020-12-01_10-13-31.png?1606785235" class="editor-image img-responsive" data-smartkarma-image-id="175693"></figure></section><section class="figure"><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/175/699/original/2020-12-01_10-22-36.png?1606785767" class="editor-image img-responsive" data-smartkarma-image-id="175699"></figure></section><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/175/700/original/2020-12-01_10-23-41.png?1606785833" class="editor-image img-responsive" data-smartkarma-image-id="175700"></figure></section><p><strong><a href="https://www.dropbox.com/s/7b61jl02dh0pzno/2020-11-25_12-43-55.png?dl=0" target="_blank" rel="noopener">EX-GROWTH SELLS</a></strong> - In the <strong>DETAIL</strong> section below, we shall review the current Ex-Growth Sells. The is the last Insight in this four-part mini-series. The first three Insights can be found at - <a href="https://www.smartkarma.com/insights/japan-four-quadrants-contrarian-buys" target="_blank" data-smartkarma-citation="insights:45688" rel="noopener">Contrarian Buys,</a> <a href="https://www.smartkarma.com/insights/japan-four-quadrants-contrarian-sells" target="_blank" data-smartkarma-citation="insights:45725" rel="noopener">Contrarian Sells</a>, and <a href="https://www.smartkarma.com/insights/japan-four-quadrants-turnaround-buys" target="_blank" data-smartkarma-citation="insights:45829" rel="noopener">Turnaround Buys</a>.   </p></section>
</div>

Source for all charts &amp; tables: Japan Analytics FOUR QUADRANTS - By combining our two scoring methodologies - the Relative Price Score (RPS) and the Results &amp; Revision Score (RRS), we can assign companies into four quadrants:-


CONTRARIAN BUYS - Low Results &amp; Revision and Relative Price Scores

CONTRARIAN SELLS - High Results &amp; Revision and Relative Price Scores

TURNAROUND BUYS - High Results &amp; Revision Scores &amp; low Relative Price Scores

EX-GROWTH SELLS - Low Results &amp; Revision Scores &amp; high Relative Price Scores

The Ex-Growth Sells quadrant offers more fertile ground for shorting as the decline in earnings momentum is already clear, however, in many cases, the market is reluctant to sell the 'darlings' of the past. Examples of profitable Ex-Growth Sells from 2020 are Kyudenko(1959 JP), Ariake Japan (2815 JP), and Santen Pharmaceutical (4536 JP). 
EX-GROWTH SELLS - In the DETAIL section below, we shall review the current Ex-Growth Sells. The is the last Insight in this four-part mini-series. The first three Insights can be found at - Contrarian Buys, Contrarian Sells, and Turnaround Buys.   


🇯🇵 JAPAN • Four Quadrants - Ex-Growth Sells

HBM Holdings Limited / Equity Capital Markets

<p>Pre-revenue biotechnology company Harbour Biomed looks to raise US$230 million in an IPO on the HKEX. Because of the short timetable for the offering, the analysis in this Insight will be shorter than normal. We think that the proposed pre-money valuation of US$950 -1,043MM is fair, and the company has rich newsflow and numerous catalysts ahead in 2021/22. We would take the deal.</p>

Pre-revenue biotechnology company Harbour Biomed looks to raise US$230 million in an IPO on the HKEX. Because of the short timetable for the offering, the analysis in this Insight will be shorter than normal. We think that the proposed pre-money valuation of US$950 -1,043MM is fair, and the company has rich newsflow and numerous catalysts ahead in 2021/22. We would take the deal.

Harbour Biomed IPO: Positive Thoughts in Brief

Japan

SANTEN PHARMACEUTICAL CO., LTD. produces and sells ophthalmic medicine.  The Company manufactures a variety of products including eye drops and ointments. Santen Pharmaceutical also imports lenses and tools and equipment used by optometrists and produces anti-rheumatic drugs.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Santen Pharmaceutical (4536 JP)

🇯🇵 JAPAN • Results & Revisions 04/13 - Pasona (Grata) & J Front Retailing

RESULTS - Only 38% of Tuesdays 69 results announcements scored positively. Of the largest-cap stocks reporting, Toho (9602 JP) cinemas has yet to...

Campbell Gunn

Video: Oxford Biomedica – executive interview

Why are investors buying into Oxford Biomedica (LN:OXB)? In this interview, BBC broadcaster Vivienne Parry OBE asks CEO John Dawson why Oxford...

Edison Investment Research

Zhaoke Ophthalmology: Bringing Focus to China

Zhaoke Ophthalmology is a pre-revenue pharmaceutical company specializing in ophthalmic drugs for China that has filed to list on the HKEX. Lee's...

Kemp Dolliver, CFA

🇯🇵 JAPAN • Four Quadrants - Ex-Growth Sells

EX-GROWTH SELLS - In the DETAIL section below, we shall review the current Ex-Growth Sells. The is the last Insight in this four-part mini-series.

Campbell Gunn

Harbour Biomed IPO: Positive Thoughts in Brief

This Insight includes a brief analysis of Harbour Biomed and its proposed listing on the HKEX. We like the deal at the price range offered.

Kemp Dolliver, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

🇯🇵 JAPAN • Results & Revisions 04/​​​​​​13 - Pasona (Grata) & J Front Retailing

RESULTS - Only 38% of Tuesdays 69 results announcements scored positively. Of the largest-cap stocks reporting, Toho (9602 JP) cinemas has yet to...

Campbell Gunn

Video: Oxford Biomedica – executive interview

Why are investors buying into Oxford Biomedica (LN:OXB)? In this interview, BBC broadcaster Vivienne Parry OBE asks CEO John Dawson why Oxford...

Edison Investment Research

Zhaoke Ophthalmology: Bringing Focus to China

Zhaoke Ophthalmology is a pre-revenue pharmaceutical company specializing in ophthalmic drugs for China that has filed to list on the HKEX. Lee's...

Kemp Dolliver, CFA

🇯🇵 JAPAN • Four Quadrants - Ex-Growth Sells

EX-GROWTH SELLS - In the DETAIL section below, we shall review the current Ex-Growth Sells. The is the last Insight in this four-part mini-series.

Campbell Gunn

Harbour Biomed IPO: Positive Thoughts in Brief

This Insight includes a brief analysis of Harbour Biomed and its proposed listing on the HKEX. We like the deal at the price range offered.

Kemp Dolliver, CFA

🇯🇵 JAPAN • Results & Revisions 04/13 - Pasona (Grata) & J Front Retailing